Combining T-cell vaccination and application of agonistic anti-GITR mAb (DTA-1) induces complete eradication of HPV oncogene expressing tumors in mice

Journal of Immunotherapy

Volumn 33, Issue 2, 2010, Pages 136-145

  Hoffmann, Corinna ^a   Stanke, Jonas ^a   Kaufmann, Andreas M ^a   Loddenkemper, Christoph ^a   Schneider, Achim ^a   Cichon, Günter ^a  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

Author keywords

Adenovirus; Cervical cancer; GITR receptor; HPV; Papillomavirus oncogenes; Therapeutic vaccine

Indexed keywords

ADENOVIRUS VECTOR; CANCER VACCINE; CD4 ANTIBODY; DTA 1; EPITOPE; GLUCOCORTICOID INDUCED TUMOR NECROSIS FACTOR RECEPTOR ANTIBODY; IMIQUIMOD; MONOCLONAL ANTIBODY; PROTEIN E6; PROTEIN E7; RECEPTOR ANTIBODY; RECOMBINANT ALPHA2A INTERFERON; T LYMPHOCYTE VACCINE; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER GROWTH; CANCER SIZE; CONTROLLED STUDY; CYTOTOXIC T LYMPHOCYTE; DRUG EFFECT; DRUG SAFETY; EXPERIMENTAL NEOPLASM; FEMALE; GENE EXPRESSION; GENE FUSION; HUMAN PAPILLOMAVIRUS TYPE 16; HUMAN PAPILLOMAVIRUS TYPE 18; MOLECULAR CLONING; MOUSE; NONHUMAN; ONCOGENE; PRIORITY JOURNAL; REGULATORY T LYMPHOCYTE; UTERINE CERVIX CANCER; VACCINATION; VIRUS CARCINOGENESIS;

ADENOVIRIDAE; ANIMALS; ANTIBODIES, MONOCLONAL; CANCER VACCINES; CELL LINE, TUMOR; DISEASE MODELS, ANIMAL; EPITOPES, T-LYMPHOCYTE; FEMALE; FIBROSARCOMA; FORKHEAD TRANSCRIPTION FACTORS; GENETIC ENGINEERING; HUMAN PAPILLOMAVIRUS 16; HUMAN PAPILLOMAVIRUS 18; HUMANS; INTERFERON-GAMMA; LYMPHOCYTE ACTIVATION; MICE; MICE, INBRED C57BL; NEOPLASM TRANSPLANTATION; ONCOGENE PROTEINS, VIRAL; RECEPTORS, NERVE GROWTH FACTOR; RECEPTORS, TUMOR NECROSIS FACTOR; RECOMBINANT FUSION PROTEINS; T-LYMPHOCYTES; TUMOR BURDEN; UTERINE CERVICAL NEOPLASMS;

EID: 77649093452     PISSN: 15249557     EISSN: None     Source Type: Journal    
DOI: 10.1097/CJI.0b013e3181badc46     Document Type: Article

References (61)

1. Schneider A, Meinhardt G, Kirchmayr R, et al. Prevalence of human papillomavirus genomes in tissues from the lower genital tract as detected by molecular in situ hybridization. Int J Gynecol Pathol. 1991;10:1-14.
2. De Villiers EM, Wagner D, Schneider A, et al. Human papillo-mavirus infections in women with and without abnormal cervical cytology. Lancet. 1987;2:703-706.
3. Fischer U, Raptis G, Gessner W, et al. Epidemiology and pathogenesis of cervical cancer. Zentralbl Gynakol. 2001;123: 198-205.
4. Dietl J, Semm K, Hedderich J, et al. CIN and preclinical cervical carcinoma. A study of morbidity trends over a 10-year period. Int J Gynaecol Obstet. 1983;21:283-289.
5. Garland SM, Hernandez-Avila M, Wheeler CM, et al. Quadrivalent vaccine against human papillomavirus to prevent anogenital diseases. N Engl J Med. 2007;356:1928-1943. (Pubitemid 46740303)
6. Doorbar J. Molecular biology of human papillomavirus infection and cervical cancer. Clin Sci (Lond). 2006;110:525-541.
7. Nindl I, Rindfleisch K, Lotz B, et al. Uniform distribution of HPV 16 E6 and E7 variants in patients with normal histology, cervical intra-epithelial neoplasia and cervical cancer. Int J Cancer. 1999;82:203-207.
8. Sheets EE, Urban RG, Crum CP et al. Immunotherapy of human cervical high-grade cervical intraepithelial neoplasia with microparticle-delivered human papillomavirus 16 E7 plasmid DNA. Am J Obstet Gynecol. 2003;181:916-926.
9. Santin AD, Bellone S, Palmieri M, et al. Induction of tumor-specific cytotoxicity in tumor infiltrating lymphocytes by HPV16 and HPV18 E7-pulsed autologous dendritic cells in patients with cancer of the uterine cervix. Gynecol Oncol. 2003;89:271-280. (Pubitemid 36457876)
10. Muderspach L, Wilczynski S, Roman L, et al. A phase I trial of a human papillomavirus (HPV) peptide vaccine for women with high-grade cervical and vulvar intraepithelial neoplasia who are HPV 16 positive. Clin Cancer Res. 2000;6:3406-3416.
11. Kaufmann AM, Nieland JD, Jochmus I, et al. Vaccination trial with HPV16 L1E7 chimeric virus-like particles in women suffering from high grade cervical intraepithelial neoplasia (CIN 2/3). Int J Cancer. 2007;121:2794-2800.
12. Hallez S, Simon P, Maudoux F, et al. Phase I/II trial of immunogenicity of a human papillomavirus (HPV) type 16 E7 protein-based vaccine in women with oncogenic HPV-positive cervical intraepithelial neoplasia. Cancer Immunol Immunother. 2004;53:642-650.
13. Garcia-Hernandez E, Gonzalez-Sanchez JL, Andrade-Manzano A, et al. Regression of papilloma high-grade lesions (CIN 2 and CIN 3) is stimulated by therapeutic vaccination with MVA E2 recombinant vaccine. Cancer Gene Ther. 2006;13:592-597.
14. Frazer IH, Quinn M, Nicklin JL, et al. Phase 1 study of HPV16-specific immunotherapy with E6E7 fusion protein and ISCOMATRIX adjuvant in women with cervical intraepithe-lial neoplasia. Vaccine. 2004;23:172-181.
15. Fiander AN, Tristram AJ, Davidson EJ, et al. Prime-boost vaccination strategy in women with high-grade, noncervical anogenital intraepithelial neoplasia: clinical results from a multi-center phase II trial. Int J Gynecol Cancer. 2006;16:1075-1081.
16. Ferrara A, Nonn M, Sehr P, et al. Dendritic cell-based tumor vaccine for cervical cancer II: results of a clinical pilot study in 15 individual patients. J Cancer Res Clin Oncol. 2003;129: 521-530.
17. de Jong A, O'Neill T, Khan AY, et al. Enhancement of human papillomavirus (HPV) type 16 E6 and E7-specific T-cell immunity in healthy volunteers through vaccination with TA-CIN, an HPV16 L2E7E6 fusion protein vaccine. Vaccine. 2002;20:3456-3464.
18. Tomasi TB, Magner WJ, Khan AN. Epigenetic regulation of immune escape genes in cancer. Cancer Immunol Immunother. 2006;55:1159-1184.
19. Seliger B. Strategies of tumor immune evasion. BioDrugs. 2005;19:347-354.
20. Gajewski TF, Meng Y, Harlin H. Immune suppression in the tumor microenvironment. J Immunother. 2006;29:233-240.
21. Chang CC, Ferrone S. Immune selective pressure and HLA class I antigen defects in malignant lesions. Cancer Immunol Immunother. 2007;56:227-236.
22. Blank C, Mackensen A. Contribution of the PD-L1/PD-1 pathway to T-cell exhaustion: an update on implications for chronic infections and tumor evasion. Cancer Immunol Immunother. 2007;56:739-745.
23. Schon MP, Schon M. Imiqimod: Mode of action. Br J Dermatol. 2007;157(suppl 2):8-13.
24. Moore RA, Edwards JE, Hopwood J, et al. Imiquimod for the treatment of genital warts: a quantitative systematic review. BMC Infect Dis. 2001;1:3.
25. Yu P, Lee Y, Liu W, et al. Intratumor depletion of CD4+ cells unmasks tumor immunogenicity leading to the rejection of late-stage tumors. J Exp Med. 2005;201:779-791.
26. Antonelli G. Biological basis for a proper clinical application of alpha-interferons. New Microbiol. 2008;31:305-318.
27. Sikorski M, Zrubek H. Recombinant human interferon gamma in the treatment of cervical intraepithelial neoplasia (CIN) associated with human papillomavirus (HPV) infection. Eur J Gynaecol Oncol. 2003;24:147-150. (Pubitemid 36389357)
28. Frost L, Skajaa K, Hvidman LE, et al. No effect of intralesional injection of interferon on moderate cervical intraepithelial neoplasia. Br J Obstet Gynaecol. 1990;97:626-630.
29. Yliskoski M, Syrjanen K, Syrjanen S, et al. Systemic alpha-interferon (Wellferon) treatment of genital human papillomavirus (HPV) type 6, 11, 16, and 18 infections: double-blind, placebo-controlled trial. Gynecol Oncol. 1991; 43:55-60.
30. Ko K, Yamazaki S, Nakamura K, et al. Treatment of advanced tumors with agonistic anti-GITR mAb and its effects on tumor-infiltrating Foxp3+CD25+CD4+ regulatory T cells. J Exp Med. 2005;202:885-891.
31. Ramirez-Montaqut T, Chow A, Hirschhorn-Cymerman D, et al. Glucocorticoid-induced TNF receptor family related gene activation overcomes tolerance/ignorance to melanoma differentiation antigens and enhances antitumor immunity. J Immunol. 2006;176:6434-6442.
32. Baessler T, Krusch M, Schmiedel BJ, et al. Glucocorticoid-induced tumor necrosis factor receptor-related protein ligand subverts immunosurveillance of acute myeloid leukemia in humans. Cancer Res. 2009;69:1037-1045.
33. Liu B, Li Z, Mahesh SP, et al. Glucocorticoid-induced tumor necrosis factor receptor negatively regulates activation of human primary natural killer (NK) cells by blocking pro-liferative signals and increasing NK cell apoptosis. J Biol Chem. 2008;283:2802-2810.
34. Baltz KM, Krusch M, Bringmann A, et al. Cancer immuno-editing by GITR (glucocorticoid-induced TNF-related protein) ligand in humans: NK cell/tumor cell interactions. FASEB J. 2007;21:2442-2454.
35. Motoyama S, Ladines-Llave CA, Luis VS, et al. The role of human papilloma virus in the molecular biology of cervical carcinogenesis. Kobe J Med Sci. 2004;50:9-19.
36. Thomas M, Pim D, Banks L. The role of the E6-p53 interaction in the molecular pathogenesis of HPV. Oncogene. 1999;18:7690-7700.
37. Brehm A, Miska EA, McCance DJ, et al. Retinoblastoma protein recruits histone deacetylase to repress transcription. Nature. 1998;391:597-601.
38. Klingelhutz AJ, Foster SA, McDougall JK. Telomerase activation by the E6 gene product of human papillomavirus type 16. Nature. 1996;380:79-82.
39. Huibregtse JM, Scheffner M, Howley PM. Localization of the E6-AP regions that direct human papillomavirus E6 binding, association with p53, and ubiquitination of associated proteins. Mol Cell Biol. 1993;13:4918-4927.
40. Kanda T, Zanma S, Watanabe S, et al. Two immunodominant regions of the human papillomavirus type 16 E7 protein are masked in the nuclei of monkey COS-1 cells. Virology. 1991; 182:723-731.
41. Sherman L, Schlegel R. Serum-and calcium-induced differentiation of human keratinocytes is inhibited by the E6 oncoprotein of human papillomavirus type 16. J Virol. 1996; 70:3269-3279.
42. Lee SS, Weiss RS, Javier RT. Binding of human virus oncoproteins to hDlg/SAP97, a mammalian homolog of the Drosophila discs large tumor suppressor protein. Proc Natl Acad Sci USA. 1997;94:6670-6675.
43. Kiyono T, Hiraiwa A, Fujita M, et al. Binding of high-risk human papillomavirus E6 oncoproteins to the human homo-logue of the Drosophila discs large tumor suppressor protein. Proc Natl Acad Sci USA. 1997;94:11612-11616.
44. Zhang Y, Dasgupta J, Ma RZ, et al. Structures of a human papillomavirus (HPV) E6 polypeptide bound to MAGUK proteins: mechanisms of targeting tumor suppressors by a high-risk HPV oncoprotein. J Virol. 2007;81:3618-3626
45. el Deiry WS, Tokino T, Velculescu VE, et al. WAF1, a potential mediator of p53 tumor suppression. Cell. 1993;75:817-825.
46. Polyak K, Lee MH, Erdjument-Bromage H, et al. Cloning of p27Kip1, a cyclin-dependent kinase inhibitor and a potential mediator of extracellular antimitogenic signals. Cell. 1994;78:59-66.
47. Glaunsinger BA, Lee SS, Thomas M, et al. Interactions of the PDZ-protein MAGI-1 with adenovirus E4-ORF1 and high-risk papillomavirus E6 oncoproteins. Oncogene. 2000;19:5270-5280.
48. Zwerschke W, Mazurek S, Massimi P, et al. Modulation of type M2 pyruvate kinase activity by the human papillomavirus type 16 E7 oncoprotein. Proc Natl Acad Sci USA. 1999;96: 1291-1296. (Pubitemid 29098444)
49. Borysiewicz LK, Fiander A, Nimako M, et al. A recombinant vaccinia virus encoding human papillomavirus types 16 and 18, E6 and E7 proteins as immunotherapy for cervical cancer. Lancet. 1996;347:1523-1527.
50. Lin KY, Guarnieri FG, Staveley-O'Carroll KF, et al. Treatment of established tumors with a novel vaccine that enhances major histocompatibility class II presentation of tumor antigen. Cancer Res. 1996;56:21-26.
51. Smahel M, Sima P, Ludvikova V, et al. Modified HPV16 E7 genes as DNA vaccine against E7-containing oncogenic cells. Virology. 2001;281:231-238.
52. Ohlschlager P, Pes M, Osen W, et al. An improved rearranged Human Papillomavirus Type 16 E7 DNA vaccine candidate (HPV-16 E7SH) induces an E7 wildtype-specific T cell response. Vaccine. 2006;24:2880-2893.
53. Doerfler W, Hohlweg U, Muller K, et al. Foreign DNA integration perturbations of the genome-oncogenesis. Ann N Y Acad Sci. 2001;945:276-288.
54. Coelho-Castelo AA, Trombone AP, Rosada RS, et al. Tissue distribution of a plasmid DNA encoding Hsp65 gene is dependent on the dose administered through intramuscular delivery. Genet Vaccines Ther. 2006;4:1.
55. Miao CH, Thompson AR, Loeb K, et al. Long-term and therapeutic-level hepatic gene expression of human factor IX after naked plasmid transfer in vivo. Mol Ther. 2001;3: 947-957.
56. McGrory WJ, Bautista DS, Graham FL. A simple technique for the rescue of early region I mutations into infectious human adenovirus type 5. Virology. 1988;163:614-617.
57. Mittereder N, March KL, Trapnell BC. Evaluation of the concentration and bioactivity of adenovirus vectors for gene therapy. J Virol. 1996;70:7498-7509.
58. Yamaguchi T, Sakaguchi S. Regulatory T cells in immune surveillance and treatment of cancer. Semin Cancer Biol. 2006; 16:115-123.
59. + regulatory T cells in tumor immunity. Curr Top Microbiol Immunol. 2005;293:287-302.
60. Krausz LT, Bianchini R, Ronchetti S, et al. GITR-GITRL system, a novel player in shock and inflammation. Scientific World J. 2007;7:533-566.
61. Hanabuchi S, Watanabe N, Wang YH, et al. Human plasmacytoid predendritic cells activate NK cells through glucocorticoid-induced tumor necrosis factor receptor-ligand (GITRL). Blood. 2006;107:3617-3623.